Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Bullboard Posts
Comment by jsnfernleyon Mar 22, 2010 6:12pm
329 Views
Post# 16911152

RE: RE: RE: Acquisition potential

RE: RE: RE: Acquisition potential"NOX can safely focus on drilling without the need to worry about a'take-over' until probably spring 2011 at the earliest."

Maybe.  Maybe not.

The Brett/Osisko deal is voluntary.  NOX would be more apt to be a hostile target for someone like Richmont.  They own the Camflo mill right next door.  They have a new board of directors with a corporate type agitator from the apparel industry as chairman with an ego the size of the Grand Canyon (read his bio and tell me he didn't write this himself).  They have cash, not many shares out, and have made it known they are (um, I mean he is) not happy about their lack of profit.

NOX would be a perfect fit for them.  They have the cash to get underground and get mill feed.  They can worry about open pit later.

I'm still wondering when the vultures will start to swoop down on the smaller juniors that have something (equipment, underground infrastructure, resources) seriously undervalued or without the cash to develop, and put an end to the gentlemanly deals that appear to be the norm for the junior industry.
Bullboard Posts